We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Proteins and Peptides in Tears Indicate Eye Conditions

By LabMedica International staff writers
Posted on 30 Apr 2013
Diseases such as dry eye and blepharitis (inflammation of the eyelids) change the proportions of certain proteins in normal tears.

A new test to diagnose dry eye would be especially useful because it is currently diagnosed by interview backed up by tests, which are not particularly reproducible.

Tatiana Suarez from Bioftalmik (Derio, Spain) and colleagues in Spain undertook a proteomics study using 2D PAGE to identify any potential protein biomarkers before carrying out a detailed validation study of the candidate species.

One hundred and forty-four participants were enrolled in the study, comprising 63 with dry eye, 38 with MGD and 43 healthy controls. More...
Tears were collected from 44 patients using surgical sponges, 16 with each disease, and 12 controls. The abundant protein immunoglobulin A was removed by immunoaffinity chromatography in case it swamped the less abundant proteins.

The remaining proteins were separated by 2D electrophoresis (PAGE) and their positions on the gel were identified by staining with a fluorescent dye. A total of 130 protein spots were resolved and image analysis was conducted to pinpoint the proteins which had different abundances between the three groups and these were identified by mass spectrometry.

Before refining the panel of proteins to a more manageable number that retained the predictive capability, they were screened by enzyme-linked immuno sorbent assay (ELISA) to identify the most predictive ones. Two validations steps followed in which the proteins were collected by sponge or capillary. The best classification method was achieved with the Random Forest and Naïve Bayes machine learning techniques which were trained using one set of results and confirmed on the others.

A network analysis of the 15 discriminatory proteins revealed that nine of them were directly or indirectly related. The major biological processes in which they are involved include inflammatory response, stress response, immune response, and oxidative stress response.

The final discriminatory panel obtained after refinement of the model consisted of five proteins: S100A6, annexin A1, annexin A11, cystatin-S and phospholipase A2-activating protein. Together they were able to discriminate between dry eye and control patients with high sensitivity and specificity. They could also distinguish between the dry eye, MGD, and control groups with good accuracy. The results were independent of the tear collection method.

The team will examine the biomarkers in a clinical setting and possibly develop a test for dry eye and meibomian gland dysfunction.

Related Links:
Bioftalmik




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.